Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
GLOBETECH PUBLISHING
JIB

Hypoxia-inducible Transcription Factors Trigger Metastasis in Malignant Melanoma Tumors

By BiotechDaily International staff writers
Posted on 06 May 2013
Cancer researchers have linked the hypoxia-inducible transcription factors HIF1 and HIF2 to the processes that control metastasis in melanoma tumors.

Hypoxia-inducible factors (HIFs) are transcription factors that respond to changes in available oxygen in the cellular environment, specifically, to decreases in oxygen, or hypoxia. HIFs promote the activation of genes involved in cancer initiation, progression, and metastases. Hypoxia has been shown to enhance the invasiveness and metastatic potential of tumor cells by regulating the genes involved in the breakdown of the ECM (extracellular matrix) as well as genes that control motility and adhesion of tumor cells. HIF activity is upregulated by mutated RAS, a member of the KRAS family of oncogenes, and BRAF (v-raf murine sarcoma viral oncogene homolog B1) as well as loss-of-function mutations of the PTEN gene. PTEN (phosphatase and tensin homolog), which is missing in 60% to 70% of metastatic cancers in humans, is the name of a phospholipid phosphatase protein, and gene that encodes it. The PTEN gene acts as a tumor suppressor gene thanks to the role of its protein product in regulation of the cycle of cell division, preventing cells from growing and dividing too rapidly.

Investigators at the University of North Carolina (Chapel Hill, USA) examined the molecular basis for melanoma metastasis in a genetically engineered PTEN-deficient, BRAF-mutant mouse model. In this model the activities of HIF1 and HIF2, which are usually overexpressed in melanoma tumors, can be shut down.

Results published in the April 8, 2013, online edition of the Journal of Clinical Investigation revealed that inactivation of HIF1 or HIF2 prevented metastasis without affecting primary tumor formation. Both HIF1 and HIF2 independently activated the proto-oncogene tyrosine-protein kinase SRC (v-src sarcoma (Schmidt-Ruppin A-2) viral oncogene homolog (avian)) using different signaling pathways.

The protein encoded by the SRC gene has been linked to several different cancers, and the identification of its role in melanoma may mean that existing drugs that target SRC may be adapted for treatment of malignant melanoma.

“What we are trying to do now is inhibit these pathways with drugs in the mice to see if we see a decrease of metastasis,” said first author Sara Hanna, a graduate student researcher at the University of North Carolina.

Related Links:

University of North Carolina




comments powered by Disqus

Channels

Drug Discovery

view channel

Ibuprofen May Restore Immune Function in Older Individuals

New research suggests that macrophages from the lungs of old mice respond differently to infections than those of young mice, and ibuprofen given to the mice reversed these changes. New research using lab mice suggests that the solution to more youthful immune function might already be a common over-the-counter pain reliever.... Read more

Therapeutics

view channel
Image: Hair follicle (blue) being attacked by T cells (green) (Photo courtesy of Christiano Lab/Columbia University Medical Center).

Hair Restoration Method Clones Patients’ Cells to Grow New Hair Follicles

Researchers have developed of a new hair restoration approach that uses a patient’s cells to grow new hair follicles. In addition, the [US] Food and Drugs Administration (FDA) recently approved a new drug... Read more

Lab Technologies

view channel
Image: Leica Microsystems launches the inverted research microscope platform Leica DMi8 (Photo courtesy of Leica Microsystems).

New Inverted Microscope Designed to Readily Adapt to Changing Research Demands

A new inverted microscope for biotech and other life science laboratories was designed to readily accommodate modifications and upgrades to allow it to keep current with changing research demands and interests.... Read more

Business

view channel

Collaboration of Mayo Clinic and IBM Cognitive Computer Devised to Improve Clinical Trial Research

The Mayo Clinic (Rochester, MN, USA) and IBM (Armonk, NY, USA) recently announced plans to pilot Watson, the IBM cognitive computer, to match patients more rapidly with suitable clinical trials. A proof-of-concept phase is currently ongoing, with the intent to introduce it into clinical use in early 2015.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.